C-reactive protein predicts functional decline in older adults newly diagnosed with dementia: A 5-year follow-up study

Q3 Medicine

Revista Espanola de Geriatria y Gerontologia Pub Date : 2025-08-27 DOI:10.1016/j.regg.2025.101722

Miguel Germán Borda , Tommy Cederholm , Salomón Salazar-Londoño , Luis Carlos Venegas-Sanabria , Hidetaka Wakabayashi , Mario Ulises Pérez-Zepeda , Miguel Fernando Borda , Jonathan Patricio Baldera , Dag Aarsland

{"title":"C-reactive protein predicts functional decline in older adults newly diagnosed with dementia: A 5-year follow-up study","authors":"Miguel Germán Borda , Tommy Cederholm , Salomón Salazar-Londoño , Luis Carlos Venegas-Sanabria , Hidetaka Wakabayashi , Mario Ulises Pérez-Zepeda , Miguel Fernando Borda , Jonathan Patricio Baldera , Dag Aarsland","doi":"10.1016/j.regg.2025.101722","DOIUrl":null,"url":null,"abstract":"<div><h3>Background and objectives</h3><div>With the increasing prevalence of dementia, identifying markers that predict prognosis in people newly diagnosed with the disease is crucial for developing targeted interventions and initiating early actions to improve their outcomes. On the other hand, C-reactive protein (CRP) is an easily accessible marker of inflammation. This study aims to evaluate whether CRP is a marker of weight loss, cognitive decline, functional decline, and mortality in older adults newly diagnosed with dementia.</div></div><div><h3>Methods</h3><div>We utilized data from DemVest, a longitudinal cohort study, including participants diagnosed with mild dementia due to Alzheimer's Disease (AD) or Lewy Body Dementia (LBD). CRP levels were measured at diagnosis. Main outcome measures were functional decline, weight, body mass index (BMI), cognitive decline and mortality assessed during a 5-year follow-up period after diagnosis. Demographic and clinical factors were considered as potential confounders, and we performed linear regression models for baseline and linear mixed models for longitudinal analysis.</div></div><div><h3>Results</h3><div>A total of 158 participants were included, with an average age of 75.2 years (SD 7.65). 60.8% (<em>n</em>  =62) had LBD. Elevated CRP was associated with functional decline during follow-up (Est 0.0118, <em>p</em>-value<0.001). For BMI or weight, we did not find any statistically significant associations, as well as for MMSE, and mortality.</div></div><div><h3>Conclusion</h3><div>Higher CRP levels were associated with greater functional decline in individuals newly diagnosed with dementia.</div></div>","PeriodicalId":39958,"journal":{"name":"Revista Espanola de Geriatria y Gerontologia","volume":"60 6","pages":"Article 101722"},"PeriodicalIF":0.0000,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Espanola de Geriatria y Gerontologia","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0211139X25001027","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Background and objectives

With the increasing prevalence of dementia, identifying markers that predict prognosis in people newly diagnosed with the disease is crucial for developing targeted interventions and initiating early actions to improve their outcomes. On the other hand, C-reactive protein (CRP) is an easily accessible marker of inflammation. This study aims to evaluate whether CRP is a marker of weight loss, cognitive decline, functional decline, and mortality in older adults newly diagnosed with dementia.

Methods

We utilized data from DemVest, a longitudinal cohort study, including participants diagnosed with mild dementia due to Alzheimer's Disease (AD) or Lewy Body Dementia (LBD). CRP levels were measured at diagnosis. Main outcome measures were functional decline, weight, body mass index (BMI), cognitive decline and mortality assessed during a 5-year follow-up period after diagnosis. Demographic and clinical factors were considered as potential confounders, and we performed linear regression models for baseline and linear mixed models for longitudinal analysis.

Results

A total of 158 participants were included, with an average age of 75.2 years (SD 7.65). 60.8% (n = 96) of patients had AD, and 39.2% (n = 62) had LBD. Elevated CRP was associated with functional decline during follow-up (Est 0.0118, p-value < 0.001). For BMI or weight, we did not find any statistically significant associations, as well as for MMSE, and mortality.

Conclusion

Higher CRP levels were associated with greater functional decline in individuals newly diagnosed with dementia.

查看原文本刊更多论文

c反应蛋白预测新诊断为痴呆的老年人功能下降：一项5年随访研究

背景与目的随着痴呆症患病率的增加，在新诊断的痴呆症患者中识别预测预后的标志物对于制定有针对性的干预措施和启动早期行动以改善其预后至关重要。另一方面，c反应蛋白（CRP）是一种容易获得的炎症标志物。本研究旨在评估CRP是否是新诊断为痴呆的老年人体重减轻、认知能力下降、功能下降和死亡率的标志。方法：我们利用了纵向队列研究DemVest的数据，包括被诊断为阿尔茨海默病（AD）或路易体痴呆（LBD）引起的轻度痴呆的参与者。在诊断时测量CRP水平。诊断后5年随访期间评估的主要结局指标为功能下降、体重、体重指数（BMI）、认知能力下降和死亡率。人口统计学和临床因素被认为是潜在的混杂因素，我们对基线进行了线性回归模型，对纵向分析进行了线性混合模型。结果共纳入158例受试者，平均年龄75.2岁（SD 7.65）。60.8% （n = 96）的患者患有AD， 39.2% （n = 62）的患者患有LBD。随访期间，CRP升高与功能下降相关（Est 0.0118， p值<； 0.001）。对于BMI或体重，我们没有发现任何统计学上显著的关联，以及MMSE和死亡率。结论在新诊断为痴呆的个体中，较高的CRP水平与更大的功能下降相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Revista Espanola de Geriatria y Gerontologia Medicine-Medicine (miscellaneous)

CiteScore

1.90

自引率

0.00%

发文量

审稿时长

85 days

期刊介绍： Una revista de gran prestigio por sus artículos originales de investigación y revisiones. Permite cubrir todas las áreas de la medicina pero siempre desde la atención al paciente anciano, y está presente en los más reconocidos índices internacionales.